Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Yf-Vax Articles

Sanofi Pasteur sends yellow fever vacc to combat epidemic

3 March 2008

IFFIm program celebrates first year with $912M donations to immunization projects worldwide

3 December 2007

Acambis sells Berna to Crucell for $16.5M

9 October 2006

Novartis to pay $19M settlement to Acambis

18 September 2006

Acambis looking to be profitable in 2002

18 March 2002

Aventis Pasteur MSD launches yellow fever vaccine in UK

11 February 2002

PowderJect moves into the black as vaccine sales increase

16 November 2001

Acambis starts Phase II trial of Japanese encephalitis vaccine

2 August 2001

PowderJect sets out strategy to become leading global vaccines player

5 July 2001

PowderJect in vaccine deal with UK govt

26 March 2001

Vaccines acquisition set to drive near-term growth at PowderJect

12 December 2000

Positive Phase III data for Peptides's Arilvax

5 June 2000

Peptide to file yellow fever vaccine in 2000

28 October 1999

Peptide to spin off drug development business

22 September 1999

Peptide Therapeutics sees shares plummet on allergy vaccine failure

7 July 1999

CPMP REPORTS ON JUNE MEETING ACTIONS

12 July 1993

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS